New research suggests Huntington’s disease may provide protection from cancer.
Browsing: cancer therapy
In this review, the authors discuss driving factors for the next generation of immunotherapy and target therapy, as well as how to increase the accuracy of the selection process for these therapies.
The European Commission has approved dinutuximab beta for the treatment of high-risk neuroblastoma patients over the age of 12 months, making it the only approved immunotherapy for these patients in Europe.
For the first time, researchers describe the pathological features of a severe liver-injury associated with the administration of the anti–PD-1 agent nivolumab in a patient with glioblastoma.
A recent study has identified a potential genetic biomarker, SHOX2, for predicting the survival of patients with diffuse glioma brain tumors.
Researchers have developed novel mini ‘artificial brains’ to model glioma tumor growth: the organoids could soon be used to develop personalized treatment strategies against brain cancers.
A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma
This summary guideline outlines methods for starting patients on TTFields, for monitoring patient response to therapy and provides a framework for evaluating when therapy should be re-planned.
Researchers from Yale Cancer Center (New Haven, CT, USA) have investigated the clinical benefits of chemotherapy treatment for adult medulloblastoma patients, with results suggesting that it may improve survival rates.
In this review article, the authors discuss the role of checkpoint inhibition in meningiomas and discuss the future of combined therapeutic strategies.
A key protein has been identified that could be targeted in new treatments against glioblastoma, one of the deadliest forms of brain cancer.